Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors
Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors
复制标题
DOI：
10.2215/cjn.01110905
复制
发表时间：
2006-07-01
影响因子：
9.8
通讯作者：
Suzuki, Hiromichi
中科院分区：
文献类型：
--
作者：
Kanno, Yoshihiko;Takenaka, Tsuneo;Suzuki, Hiromichi
比较血管紧张素II受体阻滞剂坎地沙坦与血管紧张素转换酶(ACE)抑制剂在抑制高血压合并非糖尿病肾病患者肾病进展方面的益处。使用血管紧张素转换酶抑制剂进行单一治疗仍然存在争议。所有患者都曾接受血管紧张素转换酶抑制剂的治疗。尽管接受了血管紧张素转换酶抑制剂的治疗，患者的尿蛋白排泄量仍超过1.0g/d。将90例高血压合并慢性肾功能不全患者随机分为两组。一组给予血管紧张素转换酶抑制剂加坎地沙坦(2~12 mg/d)，另一组仅给予血管紧张素转换酶抑制剂。目标BP是
The benefit of the add-on angiotensin II receptor blocker candesartan to angiotensin-converting enzyme (ACE) inhibitors in inhibition of progression of nephropathy in hypertensive patient with nondiabetic renal disease compared. with monotherapy with ACE inhibitors remains controversial. All patients were previously treated with ACE inhibitors. Urinary protein excretion of patients exceeded 1.0 g/d despite treatment with ACE inhibitors. Ninety hypertensive patients with chronic renal insufficiency were randomly assigned to one of two groups. One group received ACE inhibitor plus candesartan (2 to 12 mg/d), and a control group received only ACE inhibitor. The target BP was